GC021109

DRUG2 trials

Sponsors

GliaCure, Inc.

Conditions

Alzheimer's DiseaseHealthy Volunteers

Phase 1

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects

CompletedNCT02254369

GliaCure, Inc.Healthy Volunteers

Start: 2014-09-30End: 2014-12-31Target: 44Updated: 2015-02-18

Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease

CompletedNCT02386306

GliaCure, Inc.Alzheimer's Disease

Start: 2015-02-28End: 2015-10-31Updated: 2016-02-03